Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Exploring ULK family in human cancer: insights into mechanisms and therapeutic potential.

Created on 16 Aug 2026

Authors

Mengjia Li, Mengqi Zhang, Chenlin Wen, Haitao Cheng, Xintong Li, Yangyang Han

Published in

Bioorganic chemistry. Volume 181. Pages 110352. Aug 13, 2026. Epub Aug 13, 2026.

Abstract

The ULK (Unc-51-like kinase) family, a group of serine/threonine protein kinases, plays a central regulatory role in the initiation of autophagy. Autophagy has a dual role in cancer, as it can both inhibit tumor formation and promote the survival and progression of established tumors, making targeting autophagy an attractive therapeutic strategy for cancer. This review systematically explores the expression, function, and molecular mechanisms of the ULK family (including ULK1, ULK2, ULK3, ULK4, and SKT6) in various human cancers. Studies have shown that ULK family members play complex and sometimes contradictory roles in different cancer types and histological backgrounds, functioning as both tumor suppressors and oncogenes. Their functions are precisely regulated through multiple signaling pathways, such as mTOR and AMPK, and influence key cancer characteristics, including cell survival, proliferation, metabolic adaptation, metastasis, and drug resistance. Additionally, this review focuses on the latest progress in targeting the ULK family (particularly the development of selective ULK small molecule inhibitors) and their therapeutic potential as monotherapies or in combination with chemotherapy, targeted therapy, and immunotherapy. Despite challenges, such as understanding their context-dependent functions and refining biomarkers, targeting the ULK family, which represents the initiation step of autophagy, opens up a promising path for the development of novel anti-cancer therapies.

PMID:
42603538
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement